BCL2 and B-cell chronic lymphocytic leukemia: The independence of NEDD9 from the BCR (and BCL-2) encourages to further explore targeting the NEDD9 signaling axis as an alternative approach to prevent CLL homing, particularly in cases resistant to BCR inhibitors or venetoclax.